Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lewis-Eng joins Venable

This article was originally published in The Tan Sheet

Executive Summary

Former Emord & Associates principal Claudia Lewis-Eng signs on as partner at Washington, DC-based Venable Sept. 20. Lewis-Eng will be "another key member to [Venable's] growing food and drug practice," the firm says. Venable's "principal strengths run across both the FTC and FDA practices - no other firm, in my opinion, has the strength and depth of Venable's platform," according to Lewis-Eng. "I want to help build one of the country's premier dietary supplement practices," she adds. Lewis-Eng's current clients include Schiff Nutrition International, formerly Weider Nutrition International, and direct marketer AdvoCare...

You may also be interested in...



Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

NanoBio Nasal Antiseptic Launch Accelerated As COVID-19 Spikes Demand For Personal Sanitizers

“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.

COVID-19 Vaccines: Ex-FDA Leaders Urge High Bar For Emergency Use Authorization

Eschewing the standard approval mechanisms for COVID-19 vaccines is likely only appropriate in very limited high-risk populations, unless clinical efficacy outcomes are available, former FDA leaders say.

Topics

UsernamePublicRestriction

Register

PS098675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel